Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Natural killer T-like cytotoxicity” is not a molecule or receptor; it refers to the cytotoxic functional activity of NKT-like T cells (typically human CD3+ CD56+ T cells) that share features of both conventional T cells and NK cells, including high cytotoxic potential and robust cytokine secretion without classical MHC restriction. These NKT-like cells are distinct from invariant CD1d-restricted NKT (iNKT) cells and can arise among conventional CD8+ T cells that acquire NK-associated receptors and CD56 expression, correlating with enhanced cytotoxicity. Their cytotoxic mechanisms employ granzyme/perforin-mediated killing similar to NK cells and cytotoxic T lymphocytes, executed through formation of an immunological synapse and directed degranulation. Functionally, they participate in antitumor immunity, pathogen control, and immunoregulation, but their roles vary with disease context, aging, and microenvironmental cues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer T-like cytotoxicity.